This study examined the role of SETDB1 (a histone methyltransferase) in tertiary lymphoid structure (TLS) formation in hepatocellular carcinoma (HCC), using multiple mouse models (Akt/NRAS, Myc/CTNNB1 hydrodynamic, Hepa1-6 orthotopic and subcutaneous) plus clinical HCC samples, with spatial transcriptomics and multiplex staining for validation.
Setdb1 knockout induced TLS formation across all HCC models tested; mechanistically, Setdb1 loss generated cytosolic DNA, activated the cGAS pathway, upregulated Cxcl12 (driving B cell recruitment/maturation) and Zbp1 (triggering necroptosis within TLSs), and increased endogenous retroviral (ERV) expression that may serve as B cell neoantigens.
Findings are primarily from mouse models and cell lines; direct causal evidence in human HCC is limited to correlative clinical data. The role of ERVs as neoantigens is proposed but not formally proven. Specific SETDB1 inhibitors were not tested, leaving translational feasibility open.
SETDB1 inhibition may be a viable strategy to promote anti-tumor immune responses by inducing TLS formation in HCC — consider it as a potential combination target with existing immunotherapy regimens. Clinical translation will require dedicated SETDB1 inhibitor development and prospective human studies.
